Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. India
  4. NSE India Stock Exchange
  5. Sun Pharmaceutical Industries Limited
  6. News
  7. Summary
    SUNPHARMA   INE044A01036

SUN PHARMACEUTICAL INDUSTRIES LIMITED

(SUNPHARMA)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

U.S. drugmakers step up supplies as India battles COVID-19 surge

04/26/2021 | 07:03pm EDT

April 26 (Reuters) - U.S. drugmaker Merck & Co joined Gilead Sciences on Tuesday in lending support to India as the world's second-most populous country scrambles to address drug shortages and bring a raging new wave of COVID-19 cases under control.

Gilead said it would give India at least 450,000 vials of its antiviral drug remdesivir, while Merck said it was partnering with five Indian generic drugmakers to expand production and access to its experimental COVID-19 drug molnupiravir.

With the death toll from COVID-19 racing towards the 200,000-mark in India, medical supplies from across the world are being flown into the country to help overburdened hospitals struggling with a severe shortage of life-saving oxygen and drugs.

Nations including Britain, Germany and the United States have pledged support, while the World Health Organization said it was working to deliver 4,000 oxygen concentrators, calling the situation in India "beyond heartbreaking".

In addition, India expects to secure the biggest chunk of the 60 million AstraZeneca COVID-19 vaccine doses that the United States will share globally, two Indian government sources told Reuters.

Gilead said on Monday it would help boost the production of remdesivir in India, where the drug is approved for restricted emergency use to treat severe COVID-19 cases, by offering technical assistance to its manufacturing partners.

Seven Indian companies have licensed the drug from Gilead, with a total installed capacity of about 3.9 million units per month. Gilead said the companies were scaling up their batch sizes and adding new manufacturing facilities and local contract manufacturers.

Hospitals are facing supply shortages of remdesivir due to indiscriminate use. The drug is being sold at over 10 times its listed price in the black market, stoking fears of hoarding as people queue up outside clinics and millions take to social media to secure supplies.

Earlier this month, India banned the export of the drug and the active pharmaceutical ingredients (API) used to make it.

The WHO in November issued a conditional recommendation against the use of remdesivir in hospitalised patients due to doubts about its effectiveness in treating COVID-19, but India has continued to use it.

A senior Indian government health official said last week that remdesivir is only for those patients who need oxygen. "I am appealing that the hype over this medicine should be decreased, and it should be used in a rational manner," Vinod Kumar Paul said.

Merck said on Tuesday its partnership with Indian drugmakers, including Cipla Ltd and Sun Pharmaceutical Industries Ltd, will give the companies license to supply molnupiravir to India and more than 100 low- and middle-income countries after the treatment is authorized.

Merck also said it would donate more than $5 million worth of oxygen-production equipment, masks, hand sanitizers and financial aid to India.

(Reporting by Trisha Roy in Bengaluru and Sayantani Ghosh in Singapore; Additional reporting by Anuron Mitra, Manojna Madipattla and Ankur Banerjee; Editing by Arun Koyyur and Saumyadeb Chakrabarty)


ę Reuters 2021
Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA PLC -0.37% 8352 Delayed Quote.14.47%
CIPLA LIMITED 1.05% 960.9 Delayed Quote.17.19%
GILEAD SCIENCES, INC. -0.91% 66.61 Delayed Quote.14.33%
SUN PHARMACEUTICAL INDUSTRIES LIMITED 0.52% 668.5 Delayed Quote.12.86%
All news about SUN PHARMACEUTICAL INDUSTRIES LIMITED
06/15CORCEPT THERAPEUTICS INCORPORATEDá : Announces Settlement Deal for Patent Disput..
MT
06/03MEDULLOBLASTOMA PIPELINE : Emerging Therapies and Key pharma players involved by..
AQ
06/02SUN PHARMACEUTICAL INDUSTRIESá : to Launch Swiss Pharma's Postpartum Hemorrhage ..
MT
05/28Indian Stocks End in Green on Friday; Reliance Industries Rallies 6%
MT
05/27SUN PHARMACEUTICAL INDUSTRIES'á : Consolidated Profit More than Doubles in Fisca..
MT
05/27SUN PHARMACEUTICAL INDUSTRIES LTD.á : Annual results
CO
05/19Indian Stocks Snap Winning Streak on Wednesday; Tata Motors Slumps Over 5%
MT
05/10Indian Stocks Maintain Four-Day Winning Streak on Monday; Larsen and Toubro R..
MT
05/10Indian shares settle up as record high commodity prices lift metal stocks
RE
05/10India COVID cases hold close to record highs as calls widen for national lock..
RE
More news
Financials
Sales 2021 339 B 4 574 M 4 574 M
Net income 2021 37 004 M 499 M 499 M
Net cash 2021 58 736 M 792 M 792 M
P/E ratio 2021 36,8x
Yield 2021 0,50%
Capitalization 1 604 B 21 628 M 21 634 M
EV / Sales 2021 4,56x
EV / Sales 2022 4,06x
Nbr of Employees 36 000
Free-Float 82,7%
Chart SUN PHARMACEUTICAL INDUSTRIES LIMITED
Duration : Period :
Sun Pharmaceutical Industries Limited Technical Analysis Chart | SUNPHARMA | INE044A01036 | MarketScreener
Technical analysis trends SUN PHARMACEUTICAL INDUSTRIES LIMITED
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 32
Average target price 737,72 INR
Last Close Price 668,50 INR
Spread / Highest target 27,2%
Spread / Average Target 10,4%
Spread / Lowest Target -21,5%
EPS Revisions
Managers and Directors
NameTitle
Dilip Shantilal Shanghvi Managing Director & Executive Director
C. S. Muralidharan Chief Financial Officer
Israel Makov Non-Executive Chairman
Atanu Roy SVP & Chief Information Officer
Ashok I. Bhuta Compliance Officer & Senior GM-Secretarial
Sector and Competitors